Senate rulekeeper deals blows to revised ‘Big, beautiful bill’

The Senate parliamentarian has ruled that several key provisions in the revised domestic policy bill violate the Byrd rule, complicating its passage via budget reconciliation. Provisions deemed non-compliant include Medicaid carveouts for Alaska/Hawaii, an expanded Medicare orphan drug exemption, and measures blocking Biden-era Medicaid enrollment and nursing facility staffing rules, the latter impacting an estimated $23 billion in federal Medicaid spending. Conversely, provisions delaying Medicaid provider tax cuts and barring non-citizen access to Medicare and Affordable Care Act subsidies were deemed compliant. These rulings significantly alter the bill's scope and may impact critical votes needed for its simple majority passage.

Analysis

The Senate parliamentarian's recent rulings have introduced significant uncertainty and material changes to the Republican-led domestic policy bill, diminishing its scope and complicating its path to passage via budget reconciliation. Specific provisions struck down for violating the Byrd rule represent direct setbacks for certain industries and the bill's fiscal objectives. The rejection of an expanded Medicare 'orphan drug' exemption creates a headwind for pharmaceutical companies developing drugs for multiple rare diseases by exposing them to price negotiations. Furthermore, the ruling against a provision to block a Biden-era nursing facility staffing rule eliminates an estimated $23 billion in federal Medicaid savings over ten years, a net positive for facility operators but a negative for the bill's deficit-reduction goals. The failure of Medicaid carveouts for Alaska and Hawaii also weakens the bill's political viability by jeopardizing a key vote. Conversely, the parliamentarian approved delaying cuts to Medicaid provider taxes until 2028 and barring non-citizens from Medicare and ACA subsidies. These mixed outcomes, combined with the 'moderately negative' sentiment and the pending decision on Planned Parenthood funding, increase legislative risk and suggest a period of heightened volatility for impacted healthcare sub-sectors.

Key Decisions for Investors

• Investors in Managed Care Organizations (MCOs) and nursing facility operators can view the rulings as a net positive, as the failure to block Biden-era enrollment and staffing rules, coupled with a delay in provider tax cuts, removes significant near-term revenue and cost pressures.
• The rejection of the expanded 'orphan drug' exemption is a direct headwind for pharmaceutical firms; portfolios should be reviewed for exposure to companies reliant on drugs for multiple rare conditions, which now face a higher risk of Medicare price negotiation.
• Given the heightened legislative uncertainty and the bill's diminished scope, investors should monitor subsequent amendments and key senatorial votes, as the probability of the bill passing has decreased, increasing headline risk and potential volatility for exposed healthcare sub-sectors.